Viruses (Mar 2022)

Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma

  • Takuro Kameda,
  • Kotaro Shide,
  • Yuki Tahira,
  • Masaaki Sekine,
  • Seiichi Sato,
  • Junzo Ishizaki,
  • Masanori Takeuchi,
  • Keiichi Akizuki,
  • Ayako Kamiunten,
  • Haruko Shimoda,
  • Takanori Toyama,
  • Kouichi Maeda,
  • Kiyoshi Yamashita,
  • Noriaki Kawano,
  • Hiroshi Kawano,
  • Tomonori Hidaka,
  • Hideki Yamaguchi,
  • Yoko Kubuki,
  • Akira Kitanaka,
  • Hitoshi Matsuoka,
  • Kazuya Shimoda

DOI
https://doi.org/10.3390/v14040710
Journal volume & issue
Vol. 14, no. 4
p. 710

Abstract

Read online

A retrospective chart survey of the clinical features of indolent adult T-cell leukemia/lymphoma (ATL) was conducted in the Miyazaki Prefecture, Japan. This study enrolled 24 smoldering-type ATLs, 10 favorable chronic-type ATLs, and 20 unfavorable chronic-type ATLs diagnosed between 2010 and 2018. Among them, 4, 3, and 10 progressed to acute-type ATLs during their clinical course. The median survival time (MST) in smoldering-type ATL and favorable chronic-type ATL was not reached, and their 4-year overall survival (OS) was 73% and 79%, respectively. Compared with this, the prognosis of unfavorable chronic-type ATL was poor. Its MST was 3.32 years, and the 4-year OS was 46% (p = 0.0095). In addition to the three features that determine the unfavorable characteristics of chronic-type ATL, namely, increased lactate dehydrogenase, increased blood urea nitrogen, and decreased albumin, the high-risk category by the indolent ATL-Prognostic Index, which was defined by an increment of soluble interleukin-2 receptor (sIL2-R) of >6000 U/mL, could explain the poor prognosis in indolent ATL patients. The level of sIL-2R might be an indicator of the initiation of therapy for indolent ATL.

Keywords